Treating sexual desire disorders with flibanserin
The invention relates to the use of flibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire.
1. A method of treating a female hypoactive sexual desire disorder in a human adult patient, comprising orally administering a therapeutically effective amount of flibanserin to the patient to treat the female hypoactive sexual desire disorder.
2. The method according to claim 1 , wherein the amount administered is between about 0.1 mg and 400 mg per day of flibanserin.
3. The method according to claim 1 , wherein the amount administered is between about 1 mg and 300 mg per day of flibanserin.
4. The method according to claim 1 , wherein the amount administered is in a dosage unit containing between about 0.01 mg and 100 mg of flibanserin.
5. The method according to claim 1 , wherein the amount administered is in a dosage unit containing about 100 mg.
6. A method of treating a female hypoactive sexual desire disorder in a human adult patient, comprising orally administering a tablet comprising a therapeutically effective amount of flibanserin to the patient to treat the female hypoactive sexual desire disorder.
7. The method according to claim 6 , wherein the amount administered is between about 0.1 mg and 400 mg per day of flibanserin.
8. The method according to claim 6 , wherein the tablet comprises about 0.01 mg to 100 mg of flibanserin.
9. The method according to claim 6 , wherein the tablet comprises about 100 mg flibanserin.
10. The method according to claim 6 , wherein the tablet further comprises one or more excipients or carriers.
11. The method according to claim 10 , wherein the one or more excipients or carriers comprise at least one inert diluent.
12. The method according to claim 11 , wherein the at least one inert diluent is selected from calcium carbonate, calcium phosphate, lactose, and combinations thereof.
13. The method according to claim 10 , wherein the one or more excipients or carriers comprise at least one lubricant.
14. The method according to claim 13 , wherein the at least one lubricant is selected from the group consisting of magnesium stearate, talc, and combinations thereof.
15. The method according to claim 10 , wherein the one or more excipients or carriers comprise at least one distintegrant.
16. The method according to claim 15 , wherein the at least one disintegrant is selected from corn starch, alginic acid, and combinations thereof.
17. The method according to claim 10 , wherein the one or more excipients or carriers comprise at least one binder.
18. The method according to claim 17 , wherein the at least one binder is selected from starch, gelatin, and combinations thereof.
19. The method according to claim 10 , wherein the one or more excipients or carriers comprise at least one agent for delaying release.
20. The method according to claim 19 , wherein the at least one agent for delaying release is selected from carboxymethyl cellulose, cellulose acetate phthalate, polyvinyl acetate, and combinations thereof.
21. The method according to claim 6 , wherein the tablet further comprises one or more sweeteners, one or more flavor enhancers, preservatives, or a combination thereof.
22. The method according to claim 6 , wherein the tablet further comprises magnesium stearate, talc, and microcrystalline cellulose.
23. The method according to claim 22 , wherein the tablet further comprises one or both of lactose and sodium-carboxymethyl starch.
24. The method according to claim 10 , wherein the tablet comprises a compressed mixture of flibanserin and the one or more excipients or carriers.
25. The method according to claim 6 , wherein the tablet is uncoated.